The proportion of obese Indians has risen from 25 per cent in 2013 to 40 per cent in 2023, highlighting the need for ...

Researchers from Canada reviewed the results of 26 trials to determine which of the weight loss jabs are the most effective ...

Ready to crush your New Year’s health goals? These breakthrough medications offer more than weight loss—they support your ...

Eli Lilly's Tirzepatide Outshines Novo Nordisk's Semaglutide, Yet Brand Recognition Remains Strong for Novo's Products ...

After plugging billions into its manufacturing network to meet rampant demand for Mounjaro and Zepbound, Eli Lilly is looking ...

When Henry Conway hit his forties his BMI became dangerously high. After a lover said ‘I love your little dad bod’, he knew ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/95.C_N2kNfW.js ...

Experimental weight-loss drug Retatrutide shows promise, helping obese adults lose up to 22% of their weight in 48 weeks.

Both semaglutide (such as Ozempic) and tirzepatide (such as Zepbound and Mounjaro) belong to a class of medications designed to help manage metabolic disorders, particularly type 2 diabetes.

Obese adults who took the weekly injection lost up to 22% of their starting weight after 11 months — compared to just 14% over 15 months for semaglutide, the active ingredient in Ozempic and Wegovy.

Participants taking tirzepatide also lost more body weight than those taking glucagon-like peptide-1 (GLP-1) receptor agonists, which include drugs like Ozempic® and Wegovy®. Compounded ...